1006 related articles for article (PubMed ID: 32529952)
1. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists.
Yuen CK; Lam JY; Wong WM; Mak LF; Wang X; Chu H; Cai JP; Jin DY; To KK; Chan JF; Yuen KY; Kok KH
Emerg Microbes Infect; 2020 Dec; 9(1):1418-1428. PubMed ID: 32529952
[TBL] [Abstract][Full Text] [Related]
2. SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts.
Shu T; Huang M; Wu D; Ren Y; Zhang X; Han Y; Mu J; Wang R; Qiu Y; Zhang DY; Zhou X
Virol Sin; 2020 Jun; 35(3):321-329. PubMed ID: 32500504
[TBL] [Abstract][Full Text] [Related]
3. Evasion of Type I Interferon by SARS-CoV-2.
Xia H; Cao Z; Xie X; Zhang X; Chen JY; Wang H; Menachery VD; Rajsbaum R; Shi PY
Cell Rep; 2020 Oct; 33(1):108234. PubMed ID: 32979938
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase.
Ahmed-Belkacem R; Sutto-Ortiz P; Guiraud M; Canard B; Vasseur JJ; Decroly E; Debart F
Eur J Med Chem; 2020 Sep; 201():112557. PubMed ID: 32563813
[TBL] [Abstract][Full Text] [Related]
5. Activation and evasion of type I interferon responses by SARS-CoV-2.
Lei X; Dong X; Ma R; Wang W; Xiao X; Tian Z; Wang C; Wang Y; Li L; Ren L; Guo F; Zhao Z; Zhou Z; Xiang Z; Wang J
Nat Commun; 2020 Jul; 11(1):3810. PubMed ID: 32733001
[TBL] [Abstract][Full Text] [Related]
6. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.
Deng X; Buckley AC; Pillatzki A; Lager KM; Faaberg KS; Baker SC
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554697
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
Ugurel OM; Mutlu O; Sariyer E; Kocer S; Ugurel E; Inci TG; Ata O; Turgut-Balik D
Int J Biol Macromol; 2020 Nov; 163():1687-1696. PubMed ID: 32980406
[TBL] [Abstract][Full Text] [Related]
8. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19.
Yoshimoto FK
Protein J; 2020 Jun; 39(3):198-216. PubMed ID: 32447571
[TBL] [Abstract][Full Text] [Related]
9. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.
Romano M; Ruggiero A; Squeglia F; Maga G; Berisio R
Cells; 2020 May; 9(5):. PubMed ID: 32443810
[TBL] [Abstract][Full Text] [Related]
10. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
Freitas BT; Durie IA; Murray J; Longo JE; Miller HC; Crich D; Hogan RJ; Tripp RA; Pegan SD
ACS Infect Dis; 2020 Aug; 6(8):2099-2109. PubMed ID: 32428392
[TBL] [Abstract][Full Text] [Related]
11. Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response.
Vishnubalaji R; Shaath H; Alajez NM
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32646047
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2
Lehrer S; Rheinstein PH
In Vivo; 2020 Jun; 34(3 Suppl):1629-1632. PubMed ID: 32503821
[TBL] [Abstract][Full Text] [Related]
13. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway.
Li JY; Liao CH; Wang Q; Tan YJ; Luo R; Qiu Y; Ge XY
Virus Res; 2020 Sep; 286():198074. PubMed ID: 32589897
[TBL] [Abstract][Full Text] [Related]
14. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2.
Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells.
Yang S; Wu S; Yu Z; Huang J; Zhong X; Liu X; Zhu H; Xiao L; Deng Q; Sun W
Immun Inflamm Dis; 2020 Dec; 8(4):753-762. PubMed ID: 33124193
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.
Martin WR; Cheng F
J Proteome Res; 2020 Nov; 19(11):4670-4677. PubMed ID: 32907334
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
18. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.
Volk A; Hackbart M; Deng X; Cruz-Pulido Y; O'Brien A; Baker SC
J Virol; 2020 May; 94(11):. PubMed ID: 32188729
[TBL] [Abstract][Full Text] [Related]
20. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
